We prioritise the eight sustainability issues identified by our materiality assessment: setting strong anti-bribery and anticorruption controls; ensuring ethical sales and marketing; the way we interact with patients; transparency of our clinical trials; our approach to bioethics; bioethics: animals in science; ethically managing our supply chain; and having product security controls to deter counterfeiting.